Zoetis Inc. (ZTS)
| Market Cap | 53.80B |
| Revenue (ttm) | 9.47B |
| Net Income (ttm) | 2.67B |
| Shares Out | 422.13M |
| EPS (ttm) | 6.02 |
| PE Ratio | 21.21 |
| Forward PE | 18.17 |
| Dividend | $2.12 (1.66%) |
| Ex-Dividend Date | Apr 20, 2026 |
| Volume | 537,173 |
| Open | 130.05 |
| Previous Close | 131.10 |
| Day's Range | 127.81 - 130.05 |
| 52-Week Range | 115.25 - 177.00 |
| Beta | 0.96 |
| Analysts | Buy |
| Price Target | 156.20 (+22.56%) |
| Earnings Date | Feb 12, 2026 |
About ZTS
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and ... [Read more]
Financial Performance
In 2025, Zoetis's revenue was $9.47 billion, an increase of 2.28% compared to the previous year's $9.26 billion. Earnings were $2.67 billion, an increase of 7.52%.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for ZTS stock is "Buy." The 12-month stock price target is $156.2, which is an increase of 22.56% from the latest price.
News
Diamond Hill Mid Cap Fund Q4 2025 Portfolio Review
US equity markets posted positive returns once again in Q4, although the small and large portions of the market were stronger performers, returning 2.19% and 2.41%, respectively. Recently, we have fou...
Zoetis to Acquire Animal Genomics Business from Neogen®, Accelerating Precision Animal Health Innovation
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis to acquire animal genomics business from Neogen, strengthening the company's leadership in Precision Animal Health.
Top 15 High-Growth Dividend Stocks For March 2026
The March 2026 Top 15 dividend growth stocks list targets high-quality, undervalued companies with a projected 21.28% long-term CAGR and 1.13% average yield. Pure Quality and Value-focused stock selec...
Zoetis Inc. (ZTS) Presents at BofA Securities Animal Health Summit Transcript
Zoetis Inc. (ZTS) Presents at BofA Securities Animal Health Summit Transcript
Zoetis to Participate in the Bank of America Securities 2026 Animal Health Summit
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will participate in the Bank of America Securities 2026 Animal Health Summit on Thursday, February 26, 2026 at 1:15 p.m...
Impax U.S. Sustainable Economy Fund Q4 2025 Contributors And Detractors
Eli Lilly is included due to its strategic positioning with respect to sustainability opportunities, specifically in HealthCare Access and Innovation. Advanced Micro Devices is owned for its exception...
Zoetis: Why I'm Doubling Down On My Worst 2025 Pick
Zoetis is reiterated as a buy, with a 20% upside to a $159/share fair value, driven by margin expansion and a cheap valuation. ZTS delivered FY 2025 revenue of $9.5B, beating guidance, and presents ex...
Analysts Question Zoetis' Pathway To Growth As Key Segments Slide
Animal health firm Zoetis Inc. (NYSE: ZTS) on Thursday reported a fourth-quarter 2025 adjusted earnings per share of $1.48. The company beat the consensus of $1.40.
Zoetis Inc. (ZTS) Q4 2025 Earnings Call Transcript
Zoetis Inc. (ZTS) Q4 2025 Earnings Call Transcript
Zoetis forecasts strong 2026 profit, revenue on steady pet‑medicine demand
Zoetis on Thursday forecast 2026 adjusted profit and revenue above Wall Street estimates, as demand across its companion-animal portfolio and resilient international markets helped offset softer trend...
Zoetis Reports Fourth Quarter and Full Year 2025 Results
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE: ZTS), the world's leading animal health company, today reported its financial results for the fourth quarter and full year ...
Top Wall Street Forecasters Revamp Zoetis Expectations Ahead Of Q4 Earnings
Zoetis Inc. (NYSE: ZTS) will release earnings for its fourth quarter before the opening bell on Thursday, Feb. 12.
Zoetis Declares Second Quarter 2026 Dividend
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the second quarter of 2026. The dividend will ...
Artisan Global Opportunities Fund Q4 2025 Portfolio Update
Among our top contributors in Q4 were Argenx, Lam Research and Insmed. Among our biggest detractors in Q4 were Oracle, Netflix and BAE Systems. During the quarter, we initiated new positions in RTX (R...
Zoetis: Undervalued And Oversold
Zoetis, the global animal health leader, is deeply undervalued at a 19x forward P/E versus its 10-year average of 31.8x. ZTS is positioned to benefit from the secular trend of pet humanization, with 6...
Zoetis: Cheap Valuation And Attractive Product Launch Pipeline
I rate Zoetis (ZTS) a buy, citing a robust pipeline, upcoming product launches, and discounted valuation versus peers. ZTS targets new therapeutic white spaces—oncology, cardiology, and renal disease—...
Zoetis Inc. (ZTS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Zoetis Inc. (ZTS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Trade Tracker: Stephanie Link sells Eaton and buys more Zoetis, Natera
Stephanie Link, chief investment officer at Hightower, joins CNBC's "Halftime Report" to detail her latest portfolio moves.
Zoetis to Host Webcast and Conference Call on Fourth Quarter and Full Year 2025 Financial Results
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, February 12, 2026. Chief Executive Officer Krist...
Trade Tracker: Stephanie Link buys mores Zoetis
Stephanie Link, CIO at Hightower, joins CNBC's "Halftime Report" to explain why she's buying more Zoetis.
Zoetis to Participate in the 44th Annual J.P. Morgan Healthcare Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. Kristin Peck, Chief ...
Zoetis Announces Pricing of $1.75 Billion Convertible Senior Notes Offering
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE: ZTS) (the “Company” or “Zoetis”) today announced that it has priced its previously announced offering of $1.75 billion aggr...
Zoetis Announces Proposed $1.75 Billion Convertible Senior Notes Offering
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE: ZTS) (the “Company” or “Zoetis”) today announced that, subject to market conditions, it intends to offer $1.75 billion aggr...
Gabelli Pet Parents' Fund Q3 2025 Contributors And Detractors
Chewy Inc. gained 12% during the quarter as the company delivered solid results driven by higher autoship subscription activity and expanding private-label offerings. The largest contributors to Fund ...